SABS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

SABS ▼ -6.67% at T+5d

NEUTRAL call ✗ call lost -6.67% · α vs SPY -6.37% · entry $3.60 → $3.36

Next anchor: T+20d in 14d

Last close $3.33 (close Jun 12) · -7.50% from $3.60 entry

Entry anchored
May 28, 03:59 PM ET
via Databento tick

T+1d

-4.44%

call -4.44% · α -4.72%

$3.44

settled 14d ago

T+5d

-6.67%

call -6.67% · α -6.37%

$3.36

settled 10d ago

T+20d

—

call — · α —

—

in 14d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2026, highlighting its lead program SAB-142 for type 1 diabetes. The press release contains no new clinical data, financial results, or regulatory milestones — it is a routine conference participation announcement with no material impact on the company's valuation.

Actionable Insight

This is a routine conference participation announcement with no new data. The next meaningful catalyst is the SAFEGUARD Phase 2b topline readout in 2H 2027. No trading action warranted based on this filing.

Key Facts

SAB BIO will present an oral presentation at ADA 2026 (June 5-8) and a poster at FOCIS 2026 (June 9-12).
Presentations focus on SAB-142, a fully human anti-thymocyte immunoglobulin for Stage 3 type 1 diabetes.
Topline data readout for the registrational Phase 2b SAFEGUARD study expected in 2H 2027.
No new clinical data, financial figures, or regulatory decisions were disclosed in this press release.

Financial Impact

No financial impact — no new data, guidance, or material events disclosed.

Risk Factors

SAB-142 is still in clinical development with no approved product; regulatory and clinical trial risks remain.
Cash burn and financing risk for a clinical-stage biotech with no revenue.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

93% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3303527

7 reports for SABS

T+1T+5T+20T+60

100% Hit rate 5 of 5 directional calls best @ T+1▲ +11.71%Mar 10, 2026

Filters

Reports for SABS — sortable, filterable
	Type				Now
May 29, 2026 16d ago	Press Release NEUTRAL ★ 3/10	$3.60 $3.36	▼ −6.67%	▼ −6.37%	$3.33 (−7.50%)
May 12, 2026 4w ago	Press Release BEARISH ★ 7/10	$3.62 $3.56	▲ +1.66%	▲ +1.74%	$3.33 (+8.01%)
Mar 19, 2026 12w ago	Press Release NEUTRAL ★ 5/10	$3.75 $3.85	▲ +2.67%	▲ +4.82%	$3.33 (−11.20%)
Mar 19, 2026 12w ago	8-K BEARISH ★ 6/10	$3.78 $3.83	▼ −1.32%	▼ −3.53%	$3.33 (+11.90%)
Mar 18, 2026 12w ago	Press Release BEARISH ★ 6/10	$3.70 $3.82	▼ −3.24%	▼ −3.96%	$3.33 (+10.00%)
Mar 17, 2026 12w ago	Press Release BEARISH ★ 6/10	$3.70 $3.82	▼ −3.24%	▼ −3.96%	$3.33 (+10.00%)
Mar 10, 2026 13w ago	Press Release BULLISH ★ 7/10	$4.10 $4.07	▼ −0.73%	▲ +0.17%	$3.33 (−18.78%)

US Market Status

Market Closed — Opens in 3h 58m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access